Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
182
resultados
Última actualización
16/01/2026 [07:23:00]
Resultados 75 a 100 de 182
Resumen de: CN120695183A
The invention discloses application of CUL7 as a target spot in preparation of a medicine for preventing and/or treating colitis, and belongs to the technical field of medicine and pharmacology. The invention provides application of a CUL7 target spot in preparation of a medicine for preventing and/or treating colitis. The invention also provides application of CUL7 as a target spot in preparation of a preparation for diagnosing colitis, and application of a CUL7 gene inhibitor or a CUL7 protein inhibitor in preparation of a medicine for preventing and/or treating colitis. The invention proves the relationship between the CUL7 and the colitis, the CUL7 can be used as a target for preventing and treating the colitis, the CUL7 gene expression or the CUL7 intervention effect can be realized by utilizing any technology, the colitis can be effectively inhibited, and a basis is provided for the prevention, diagnosis and treatment of diseases.
Resumen de: CN120708939A
The invention discloses an inflammatory bowel disease curative effect prediction system based on multi-modal data, and relates to the field of medical information processing. The system comprises a multi-modal data acquisition module used for receiving multi-modal data; the text feature extraction module is used for determining a text feature vector by utilizing a text feature extraction model; the endoscopic intestinal mucosa feature recognition module is used for determining intestinal mucosa features by using an endoscopic intestinal mucosa feature recognition model; the image feature recognition module is used for determining iconography features by using an image feature recognition model; the pathological feature extraction module is used for determining pathological features by using the pathological recognition model; and the curative effect prediction module is used for predicting the curative effect of the biological agent based on the multi-modal data characteristics by using a Transform model and a full connection layer. Compared with the prior art, biological agent curative effect prediction based on clinical-pathology-endoscope-image multi-mode feature fusion is achieved, and the accuracy and clinical rationality of diagnosis and treatment decisions are improved.
Resumen de: AU2024242428A1
Provided herein are methods for treating or preventing pouchitis comprising administering a SMAD7 antisense oligonucleotide or pharmaceutical formulations comprising the SMAD7 antisense oligonucleotide.
Resumen de: WO2025199410A1
The disclosed method and system pertain to stratifying a patient population for precision medicine in Inflammatory Bowel Disease (IBD) treatment. The method involves accessing a multi-omic dataset comprising genomic, transcriptomic, and proteomic profiles of patient data. Machine learning algorithms are employed to analyze the dataset and identify biomarkers associated with a response to a drug for treating IBD. The patient population is stratified into phenotypic groups based on the identified biomarkers using unsupervised clustering. A patient population predicted to respond to the drug is defined based on the stratification and further analysis of patient metadata. The system includes a data storage unit and a processor configured to perform the method. The method and system can be used to optimize therapeutic interventions in IBD management.
Resumen de: CN120683281A
The invention discloses a microbial marker for treating irritable bowel on the basis of coprophilous fungus transplantation and a screening method of the microbial marker. The microbial marker is prepared from the following components: Butyrimonas faecalis, Odoribacter laneus, Parabacteroides verdea, Bacteroides eggerii, Phocaeia massiformis, Phocaeia dorrei, Phocaeia vulgaris, Bacteroides nordii, Phocaeia viscera, Muriaceae bacteria, Clostridium fesum, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces cerevisiae, Saccharomyces Through metagenome sequencing and a machine learning algorithm, the key microbial markers significantly related to intestinal stress symptom improvement in the coprophilous fungus transplantation treatment process are screened out, and a scientific basis and a standardized scheme are provided for coprophilous fungus transplantation treatment of irritable bowel.
Resumen de: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: WO2025193919A1
Methods of identifying a canine subject susceptible to inflammatory bowel disease, methods of treating or preventing inflammatory bowel disease in a canine subject, and compositions useful for treating or preventing inflammatory bowel disease in a canine subject are described herein.
Resumen de: US2025290143A1
Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohn's disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.
Resumen de: JP2025134894A
To provide a system and a method for easily and accurately detecting a defecation event and acquiring defecation event data.SOLUTION: A system 100 and a method facilitate detection and recording of a defecation event of a target such as a participant of a clinical test for treating a digestive system disease such as an irritable bowel syndrome (IBS), an inflammatory bowel disease (IBD), and chronic coprostasis. The system 100 and the method can be used by individual patients for detecting and recording a defecation event, and resultant data can be checked in detail by a medical treatment provider at the time of evaluating health and/or treatment of the gastrointestinal of the patient.SELECTED DRAWING: Figure 1
Resumen de: TW202535470A
The present disclosure generally relates to methods, and diagnostic applications, for the treatment of ulcerative colitis. More particularly the methods and diagnostic applications of the present invention relate to expression profiles of certain gene transcripts in ulcerative colitis patients and the usefulness of the expression profiles of these gene transcripts for the treatment, and/ or diagnostic use in a subgroup of patients having ulcerative colitis.
Resumen de: KR20250135709A
본 발명은 장 질환 예방 또는 치료용 조성물 및 장 질환 진단을 위한 정보제공방법에 관한 것으로, 인간의 장내 마이크로바이옴 분석을 통해 장 질환과 관련있는 유효 균주를 선별하였으며, 이들 중 크론병 등 장 질환에 치료 효과가 있는 균주를 확인하였는 바, 질병 진단 또는 장 질환의 예방, 개선 및 치료에 유용하게 활용될 수 있다.
Resumen de: WO2025185773A1
Disclosed in the present invention are an antibody targeting TL1A and the use thereof. The antibody of the present invention can be used for blocking the interaction between TL1A and DR3, is helpful for achieving the purpose of intervention from the early stages of inflammation, inhibits immune cells such as effector T cells to release cytokines for promoting an inflammatory response, and provides more possibilities for treatment methods for IBD patients or other TL1A-related diseases.
Resumen de: WO2025188870A1
Provided herein are methods of identifying a subject as having an inflammatory bowel disorder, wherein a method includes (a) determining a level of NXPE1 in a biological sample from the subject; and (b) comparing the level of NXPE1 in the biological sample to a reference level, wherein the presence of a level of NXPE1 in the biological sample above the reference level indicates that the subject has an inflammatory bowel disorder.
Resumen de: WO2025186390A1
The present invention refers to an in vitro method for predicting the response of a patient suffering from ulcerative colitis to a treatment with anti-tumor necrosis factor (TNF) antibodies.
Resumen de: CN120617394A
The invention relates to the technical field of traditional Chinese medicines, in particular to application of a qi-stagnation stomachache preparation in preparation of a medicine for treating irritable bowel syndrome. According to the application of the qi-stagnation stomachache preparation in preparation of the medicine for treating the irritable bowel syndrome, the diarrhea condition of the diarrhea type irritable bowel syndrome can be improved, meanwhile, anxiety and visceral hypersensitivity caused by the irritable bowel syndrome can be relieved, and therefore the preparation can be used for preparing the medicine for treating the qi-stagnation stomachache. The qi stagnation and stomachache preparation has a remarkable improvement effect on diarrhea type irritable bowel syndrome (IBS-D).
Resumen de: CN120617562A
The invention belongs to the technical field of biological medicine, and particularly relates to a preparation method of a magnetic resonance/fluorescence bimodal nanometer diagnosis and treatment agent based on nitrogen oxide. The preparation method comprises the following steps: firstly, respectively modifying distearoyl phosphatidyl ethanolamine phospholipid and IR780 by utilizing TEMPO to prepare DSPE-PEG-TEMPO and an ROS responsive fluorescent probe IT, then embedding the phospholipid into a macrophage cell membrane by utilizing cell membrane fluidity, and wrapping the fluorescent probe IT and curcumin in an ultrasonic and extrusion manner, so as to prepare the bionic nano diagnosis and treatment agent based on MRI/FL dual-mode imaging. Wherein the TEMPO not only has MRI (Magnetic Resonance Imaging) performance, but also can remove active oxygen; the ROS response type fluorescent probe can track the focus of the inflammatory bowel disease through fluorescence imaging and is used for surgical navigation; the anti-inflammatory drug curcumin can be slowly released at the focus part. Through the synergistic effect of the three components and the inflammation tendency of the macrophage membrane, accurate imaging and drug release treatment of the inflammatory bowel disease are expected to be realized.
Resumen de: WO2025185637A1
Provided are methods for determining the risk of, diagnosing, preventing, or treating Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Some embodiments provide kits and computer program products for determining the risk of or diagnosing Crohn's Disease (CD), ulcerative colitis (UC) and/or inflammatory bowel disease (IBD) in an individual. Other example embodiments are described herein. In certain embodiments, the disclosed methods and kits are accurate, cost-effective and non-invasive.
Resumen de: US2025281553A1
Described herein are bacteriophages that infect and lyse adherent-invasive Escherichia coli (AIEC). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with AIEC or at risk of infection by AIEC, or in the prophylactic or therapeutic treatment of diseases and conditions associated with AIEC, including inflammatory bowel disease (IBD), urinary tract infection (UTI), neonatal meningitis, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and lung cancer, in a subject in and for other uses described herein.
Resumen de: WO2024094817A1
The present invention relates to a score (TOPOSCORE) for describing eubiosis or dysbiosis in an individual, that can be used, inter alia, for determining if a patient is likely to respond to an immune-oncology treatment, more precisely, a treatment comprising administration of an immune checkpoint inhibitor (ICI). The TOPOSCORE represents a robust biomarker predicting immunosensitivity and immunoresistance to ICI on an individual basis.
Resumen de: EP4614151A1
The present invention refers to an in vitro method for predicting the response of a patient suffering from ulcerative colitis to a treatment with anti-tumor necrosis factor (TNF) antibodies.
Resumen de: AU2023327783A1
Embodiments include a method for detecting small intestinal bacterial overgrowth, SIBO, the method comprising: obtaining data representing a time series of readings from gas sensor hardware housed within an ingestible capsule device orally ingested by a subject, identifying the data corresponding to timing of passage through the small intestine, and determining whether or not the data indicates presence of SIBO.
Resumen de: CN120605330A
The invention discloses a novel application of a transient receptor potential cation channel subgroup C member 4 (TRPC4) inhibitor in preparation of a medicine for preventing or treating inflammatory bowel disease (IBD). The research finds that in a colitis mouse model, the enteritis symptom of the colitis mouse can be obviously improved by systemic gene knockout of TRPC4 or application of a TRPC4 inhibitor. Therefore, the TRPC4 is related to the disease progress of the colitis, and the TRPC4 can be used as a biomarker for screening patients and predicting the curative effect.
Resumen de: CN120590530A
The invention discloses a TL1A targeting antibody and an application thereof. The antibody provided by the invention can be used for blocking the interaction between TL1A and DR3, is helpful to achieve the purpose of intervention from the early stage of inflammation, inhibits immune cells such as effector T cells from releasing cytokines for proinflammatory reaction, and provides more possibilities for treatment methods of IBD patients or other TL1A related diseases.
Resumen de: CN120594728A
The invention discloses a method for determining the content of organic acid metabolites of dark plums in colon tissue and application. The determination method comprises the following steps: (1) adding sterilized normal saline into colon tissues, grinding, adding methanol, continuously grinding, centrifuging, taking a supernatant, adding methanol for vortex, centrifuging, and finally adding water for vortex to obtain a sample solution to be detected; (2) a high performance liquid chromatography-mass spectrometry method is adopted, citric acid, malic acid and quinic acid standard substances are used for drawing standard curves of the three organic acids, citric acid adopts a positive ion mode, and malic acid and quinic acid adopt a negative ion mode; and (3) detecting the sample to be detected by adopting the same method, and calculating the concentrations or contents of the three organic acid metabolites (citric acid, malic acid and quinic acid) according to the standard curve. The method is simple and high in sensitivity, and can be used for researching the mechanism of the smoked plum acting on the ulcerative colitis.
Nº publicación: WO2025181327A1 04/09/2025
Solicitante:
AARHUS UNIV [DK]
AARHUS UNIVERSITET
Resumen de: WO2025181327A1
The present invention relates to a method for determining a need for adjustment of parenteral supplementation, risk of developing acid-base imbalance, and monitoring development of acid-base imbalance in a subject receiving parenteral supplementation and having intestinal insufficiency, such as short bowel. In particular, the present invention relates to determining urinary net acid excretion (NAE) for evaluating acid-base imbalances in subjects having intestinal insufficiency, such as short bowel, in order to determine risk of developing and/or monitoring development of acid-base imbalance, as well as adjustment of parenteral supplementation.
BOPI
Sede Electrónica
